ReviewIndian journal of psychological medicine2026
Sex-based Differences in the Efficacy and Tolerability of Selective Serotonin Reuptake Inhibitors in Adults with Major Depressive Disorder: A Systematic Review and Meta-analysis.
Review in Indian journal of psychological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose of the Review: Sex-based differences in antidepressant outcomes may influence treatment decisions in major depressive disorder (MDD). This systematic review and meta-analysis evaluated sex-based differences in the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) in adults with MDD. Collection and Analysis of Data: PubMed, Cochrane Library, and Scopus were searched electronically, supplemented by citation searching. Two reviewers independently screened records and assessed full-text articles for eligibility. Of 3,523 records identified, 100 duplicates were removed, and 237 full-text articles were assessed, resulting in 10 included studies published between 2005 and 2025. Eligible studies included at least one SSRI arm with extractable sex-stratified outcome data specific to SSRIs. Risk of bias was assessed using RoB 2, the Newcastle-Ottawa Scale, and design-appropriate appraisal tools. Certainty of evidence was evaluated using GRADE. Pooled estimates were generated using random-effects meta-analysis. Results: Ten studies (2005-2025) were included. Remission (six studies, 3,865 participants) showed OR: 1.18 (95% CI: 0.96-1.44; Conclusions: SSRI efficacy outcomes showed a consistent female-favoring direction, clearest for continuous symptom improvement, but estimates were limited by heterogeneity, imprecision, and incomplete sex-stratified reporting. The evidence does not support sex-based prescribing; adequately powered, prospectively sex-stratified studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.